NEW YORK – Hoag Memorial Hospital Presbyterian and Exosome Sciences, a subsidiary of Aethlon Medical, have partnered to launch a study to identify and characterize potential early disease biomarkers for cancer diagnostics, cancer progression, and treatment resistance.
As part of the collaboration, the group's researchers will study exosomes in cancer patients and individuals who have a high genetic risk for cancer.
Monmouth Junction, New Jersey-based Exosome Sciences is developing diagnostic assays using biomarkers found in cancer patients' exosomes.
"Liquid biopsies have the potential to facilitate the early detection of cancer and the assessment of the efficacy of potential treatments in real time," Michael Demeure, principal investigator of the study and program director of precision medicine at Newport Beach, California- based Hoag, said in a statement.
"Hoag has an active hereditary cancer program that supports a number of individuals and families at high risk of developing cancer and is committed to achieving breakthroughs in the detection of cancer at its earliest possible and most treatable stage," Demeure added.
Financial details of the collaboration were not disclosed.
"This partnership with Hoag may significantly accelerate our development of exosome-based liquid biopsies and may provide deep insights into the detection, progression, and treatment options for cancer patients and their families," Exosome Sciences and Aethlon Medical CEO Timothy Rodell said in a statement.